Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB122 + TAS-115
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AB122 + TAS-115 is an investigational **combination regimen** consisting of **AB122** (an anti-PD-1 monoclonal antibody) and **TAS-115** (an orally administered multi-kinase inhibitor targeting MET, VEGFR, and FMS/CSF1R)[3][5][6]. The combination is being explored in several solid tumors, including unresectable metastatic non-small cell lung cancer (NSCLC) and alveolar soft part sarcoma (ASPS)[3]. AB122 acts as an immune checkpoint inhibitor, blocking the PD-1 receptor to enhance anti-tumor immune responses, while TAS-115 inhibits tumor angiogenesis, proliferation, and osteoclast-mediated bone destruction by targeting kinases involved in these pathways[2][5][6].
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MET (Mesenchymal-epithelial transition factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on AB122 + TAS-115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB122 + TAS-115.